SAVA
Cassava Sciences Inc.
NASDAQ: SAVA
$1.43+0.11 (+8.33%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$1.16 – $4.98
Avg Volume436.7K3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
No price data available.
Pipeline
Drug candidates sponsored by Cassava Sciences · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Simufilam | Alzheimer Disease+6 more | Completed | 2025-01-31past | 7 | |
| Phase 2 | Placebo oral tablet | Alzheimer Disease | Completed | 2020-03-31past | 1 | |
| Phase 2 | Simufilam 100 mg oral tablet | Alzheimer Disease | Completed | 2023-11-09past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for SAVA. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.